Radiation therapy for advanced and metastatic melanoma

Journal of Surgical Oncology

Volumn 109, Issue 4, 2014, Pages 370-375

  Fogarty, Gerald B ^a,b   Hong, Angela ^a,c  

^a MELANOMA INSTITUTE AUSTRALIA   (Australia)

^b Mater Hospital   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

clinical trial; melanoma; metastasis; radiation therapy; review

Indexed keywords

CLINICAL TRIAL; MELANOMA; METASTASIS; RADIATION THERAPY; REVIEW;

HUMANS; MELANOMA; NEOPLASM METASTASIS;

EID: 84893917595     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23509     Document Type: Review

References (49)

1. MacKee GM, Cipollaro AC, Montgomery H:, X-rays and radium in the treatment of diseases of the skin. Philadelphia: Lea & Febiger; 1946.
2. Rofstad EK:, Radiation biology of malignant melanoma. Acta Radiol Oncol 1986; 25: 1-10.
3. Stevens G, McKay MJ:, Dispelling the myths surrounding radiotherapy for treatment of cutaneous melanoma. Lancet Oncol 2006; 7: 575-583.
4. Overgaard J, Overgaard M, Hansen PV, et al.: Some factors of importance in the radiation treatment of malignant melanoma. Radiother Oncol 1986; 5: 183-192.
5. Million RR, Cassisi NJ:, Management of head and neck cancer: A multidisciplinary approach. Philadelphia: Lippincott; 1984.
6. Ang KK, Byers RM, Peters LJ, et al.: Regional radiotherapy as adjuvant treatment for head and neck malignant melanoma. Preliminary results. Arch otolaryngol 1990; 116: 169-172.
7. Turesson I, Notter G:, The influence of fraction size in radiotherapy on the late normal tissue reaction-I: Comparison of the effects of daily and once-a-week fractionation on human skin. Int J Radiat Oncol 1984; 10: 593-598.
8. Overgaard J, von der Maase H, Overgaard M:, A randomized study comparing two high-dose per fraction radiation schedules in recurrent or metastatic malignant melanoma. Int J Radiat Oncol 1985; 11: 1837-1839.
9. Sause WT, Cooper JS, Rush S, et al.: Fraction size in external beam radiation therapy in the treatment of melanoma. Int J Radiat Oncol 1991; 20: 429-432.
10. Kingsley DP:, An interesting case of possible abscopal effect in malignant melanoma. Br J Radiol 1975; 48: 863-866.
11. Postow MA, Callahan MK, Barker CA, et al.: Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012; 366: 925-931.
12. Stamell EF, Wolchok JD, Gnjatic S, et al.: The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol 2013; 85: 293-295.
13. Marcus DM, Lowe M, Khan MK, et al.: Prognostic factors for overall survival after radiosurgery for brain metastases from melanoma. Am J Clin Oncol 2013. Feb 20. doi: 10.1097/COC.0b013e318280d7be
14. Fumagalli I, Bibault JE, Dewas S, et al.: A single-institution study of stereotactic body radiotherapy for patients with unresectable visceral pulmonary or hepatic oligometastases. Radiat Oncol 2012; 7: 164.
15. Hawkins BS:, Collaborative ocular melanoma study randomized trial of I-125 brachytherapy. Clin Trials 2011; 8: 661-673.
16. Chaudhuri A, De-Groot C, Seel M, et al.: Treatment of regional cutaneous nodular metastases from melanoma using high-dose rate mould brachytherapy. J Med Imag Radiat Oncol 2011; 55: 206-212.
17. Hobbs C, Harper J:, The use of high dose rate brachytherapy palliation after failed palliative external beam radiotherapy for a cutaneous malignant melanoma of the foot: A case report. J Palliat Med 2011; 14: 521-523.
18. Vtyurin BM, Medvedev VS, Anikin VA, et al.: Neutron brachytherapy in the treatment of melanoma. Int J Radiat Oncol 1994; 28: 703-709.
19. Elidan J, Sela M, Lijovetzky G, et al.: Metastatic maxillary sinus melanoma treated by local excision and brachytherapy. J Otolaryngol 1989; 18: 293-297.
20. Manning MR, Cetas TC, Miller RC, et al.: Clinical hyperthermia: Results of a phase I trial employing hyperthermia alone or in combination with external beam or interstitial radiotherapy. Cancer 1982; 49: 205-216.
21. Fogarty GB, Ng D, Liu G, et al.: Volumetric modulated arc therapy is superior to conventional intensity modulated radiotherapy-A comparison among prostate cancer patients treated in an Australian centre. Radiat Oncol 2011; 6: 108.
22. Awad R, Fogarty G, Hong A, et al.: Hippocampal avoidance with volumetric modulated arc therapy in melanoma brain metastases-The first Australian experience. Radiat Oncol 2013; 8: 62.
23. Gondi V, Hermann BP, Mehta MP, et al.: Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors. Int J Radiat Oncol 2013; 85: 348-354.
24. Gondi V, Mehta MP, Pugh S, et al.: Memory Preservation with Conformal Avoidance of the Hippocampus during Whole-Brain Radiotherapy (WBRT) for Patients with Brain Metastases: Primary Endpoint Results of RTOG 0933. In "2013 American Society for Radiation Oncology (ASTRO) 55th Annual Meeting." Atlanta, USA, 2013.
25. Wang Z, Nabhan M, Schild SE, et al.: Charged particle radiation therapy for uveal melanoma: A systematic review and meta-analysis. Int J Radiat Oncol 2013; 86: 18-26.
26. Hong A, Fogarty G:, Role of radiation therapy in cutaneous melanoma. Cancer J 2012; 18: 203-207.
27. Mendenhall WM, Shaw C, Amdur RJ, et al.: Surgery and adjuvant radiotherapy for cutaneous melanoma considered high-risk for local-regional recurrence. Am J Otolaryngol 2013; 34: 320-322.
28. Weinstock MA, Sober AJ:, The risk of progression of lentigo maligna to lentigo maligna melanoma. Br J Dermatol 1987; 116: 303-310.
29. Stevenson O, Ahmed I:, Lentigo maligna: Prognosis and treatment options. Am J Clin Dermatol 2005; 6: 151-164.
30. Kelly JW:, Following lentigo maligna may not prevent the development of life-threatening melanoma. Arch Dermatol 1992; 128: 657-660.
31. Michalik EE, Fitzpatrick TB, Sober AJ:, Rapid progression of lentigo maligna to deeply invasive lentigo maligna melanoma. Report of two cases. Arch Dermatol 1983; 119: 831-835.
32. Fogarty GB, Hong A, Scolyer RA, et al.: Radiotherapy for lentigo maligna-A literature review and recommendations for treatment. Br J Dermatol 2013. Sep 6. doi: 10.1111/bjd.12611
33. Benlyazid A, Thariat J, Temam S, et al.: Postoperative radiotherapy in head and neck mucosal melanoma: A GETTEC study. Arch Otolaryngol 2010; 136: 1219-1225.
34. Christopherson K, Malyapa RS, Werning JW, et al.: Radiation therapy for mucosal melanoma of the head and neck. Am J Clin Oncol 2013. Apr 3. doi: 10.1097/COC.0b013e31828d73bf
35. Diaz R, Moral P, Fonfria M, et al.: Multimodality management of a locally advanced primary oesophageal melanoma with radical surgery and adjuvant chemoimmunoradiotherapy. Clin Transl Oncol 2010; 12: 306-309.
36. Ozyigit G, Cengiz M, Yazici G, et al.: Robotic stereotactic body radiotherapy in the treatment of sinonasal mucosal melanoma: Report of four cases. Head Neck 2013; 35: E69-E73.
37. Henderson MA, Burmeister BH, Ainslie J, et al.: Adjuvant radiotherapy after lymphadenectomy in melanoma patients: Final results of an intergroup randomized trial (ANZMTG 0.JT1.02/TROG 02.01). J Clin Oncol 2013; 31: abstr 9001.
38. Margolin K:, Ipilimumab in a Phase II trial of melanoma patients with brain metastases. Oncoimmunology 2012; 1: 1197-1199.
39. Long GV, Trefzer U, Davies MA, et al.: Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): A multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13: 1087-1095.
40. Fogarty G, Morton RL, Vardy J, et al.: Whole brain radiotherapy after local treatment of brain metastases in melanoma patients-a randomised phase III trial. BMC Cancer 2011; 11: 142.
41. Kishi K, Tamura S, Mabuchi Y, et al.: Percutaneous interstitial brachytherapy for adrenal metastasis: Technical report. J Radiat Res 2012; 53: 807-814.
42. Magnuson WJ, Halligan JB:, Successful treatment of melanoma metastatic to the left atrium using external beam radiation therapy. Oncology 2010; 24: 650-653.
43. Jang HS, Spillane A, Boyle F, et al.: Radiotherapy can cause haemostasis in bleeding skin malignancies. Case Reports Med 2012; 2012: 168681.
44. Seegenschmiedt MH, Keilholz L, Altendorf-Hofmann A, et al.: Palliative radiotherapy for recurrent and metastatic malignant melanoma: Prognostic factors for tumor response and long-term outcome: A 20-year experience. Int J Radiat Oncol 1999; 44: 607-618.
45. Bahadoran P, Allegra M, Le Duff F, et al.: Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma. J Clin Oncol 2013; 31: e324-e326.
46. Boussemart L, Boivin C, Claveau J, et al.: Vemurafenib and radiosensitization. JAMA Dermatol 2013; 149: 855-857.
47. Salama AK, Flaherty KT:, BRAF in melanoma: Current strategies and future directions. Clin Cancer Res 2013; 19: 4326-4334.
48. Burmeister BH, Henderson MA, Ainslie J, et al.: Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: A randomised trial. Lancet Oncol 2012; 13: 589-597.
49. Read J:, Recent advances in cutaneous melanoma: Towards a molecular model and targeted treatment. Aust J Dermatol 2013; 54: 163-172.